Prostate cancer (PCa) is the second most common type of cancer among men in Western societies.
Once in the castrate-resistant metastatic setting therapeutic options are limited. The importance of angiogenesis in the progression of PCa has been widely reported providing a rationale to test anti-angiogenic compounds for PCa treatment in clinical trials (CTs). However, in spite of the promising results shown in preclinical models and some anti-tumor activity observed in CTs, to date, no angiogenic inhibitor has been approved for use in PCa. This editorial outlines the latest clinical evidence regarding anti-angiogenic therapies in PCa treatment.
Written by:
Martínez-Jabaloyas JM, March-Villalba JA, Navarro-García MM, Dasi F. Are you the author?
Fundación Investigación Hospital Clínico Universitario de Valencia. Instituto de Investigación INCLIVA, Avda. Blasco Ibáñez 17, E-46010 Valencia, Spain.
Reference: Expert Opin Biol Ther. 2012 Oct 24. Epub ahead of print.
doi: 10.1517/14712598.2013.733366
PubMed Abstract
PMID: 23094957
UroToday.com Prostate Cancer Section
